Ocrevus (ocrelizumab) is a humanized monoclonal antibody developed to treat MS. It is the first therapy approved in both the U.S. and Europe to treat both relapsing forms of MS and primary progressive MS, the latter of which had no approved treatments previously in the U.S. or the EU.
Most relapsing-remitting multiple sclerosis (RRMS) patients switching to Ocrevus (ocrelizumab) following suboptimal responses to other disease-modifying therapies (DMTs) show no evidence of disease activity, according to final two-year data from the European-based CASTING Phase 3b trial. These…
Read morePeople with relapsing-remitting multiple sclerosis (RRMS) who switch to Ocrevus (ocrelizumab) after discontinuing Gilenya (fingolimod) have fewer relapses than those who switch to Mavenclad (cladribine) or Tysabri (natalizumab), according to a new study. Rates of disability…
Ocrevus (ocrelizumab), an anti-CD20 therapy developed by Genentech, seems to be superior to rituximab at lowering relapse rates among patients with relapsing-remitting multiple sclerosis (RRMS), according to data from two large MS registries. Overall, the findings…
Autologous hematopoietic stem cell transplant (aHSCT) is superior to Gilenya (fingolimod) and Tysabri (natalizumab) at preventing relapses and reducing disability in people with highly active relapsing-remitting multiple sclerosis (RRMS). In turn, aHSCT appears to be as…
Treatment with Ocrevus (ocrelizumab) before or during pregnancy does not seem to increase the risk of major pregnancy or infant complications, with 79% of the pregnancies leading to live births, according to data from more than 2,000 women…
Nearly 80% of people with early-stage relapsing-remitting multiple sclerosis (RRMS) show no evidence of disease activity after two years of treatment with Ocrevus (ocrelizumab), according to updated data from the ENSEMBLE Phase 3b trial. More than 88%…
Something is happening to me. All four limbs have become heavier than usual over the past two weeks. My arms and fingers are stiffer and less responsive, and I’ve somehow managed to effect a shuffling gait in my wheelchair.
Off-label use of high-efficacy disease modifying therapies (DMTs) for people with progressive forms of multiple sclerosis (MS) appear to be as effective as on-label, or approved, DMTs for this MS patient group, a review study from Brazil suggests.
People with multiple sclerosis (MS) who are on therapies that deplete antibody-producing B-cells can mount an effective T-cell immune response to COVID-19 vaccination, a new study shows. The findings suggest that the vaccines strongly activate other parts…
In December 2019, I was stopped in my tracks, or rather wheels, as I was about to have my third infusion of Ocrevus (ocrelizumab), the multiple sclerosis disease-modifying therapy (DMT) that I’d been taking every six months…
Two years of treatment with Ocrevus (ocrelizumab) outperformed Rebif (interferon beta-1a) at preventing myelin loss in people with relapsing multiple sclerosis (MS), according to a new analysis of data from the OPERA II clinical trial. Ocrevus’…
Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.
Get regular updates to your inbox.